|
WO2020053816A1
|
|
Crystalline forms of a quinazole compound and its hydrochloride salts
|
|
TW201925207A
|
|
Salts of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-D]pyrimidine-7-carboxamide, and crystalline forms thereof
|
|
WO2018004290A1
|
|
Novel pyrazole derivative as alk5 inhibitor and uses thereof
|
|
WO2018004258A1
|
|
Novel heterocyclic derivative compound and use thereof
|
|
BRPI0814097A2
|
|
Cm insulinotropic peptide derivative your modified n-terminal amino acid
|
|
JP2009019027A
|
|
Insulin secretion peptide derivative in which amino acid of amino terminal is varied
|
|
JP2008169195A
|
|
Insulinotopic peptide drug combo using carrier material
|
|
CN101258164A
|
|
A method for the mass production of immunoglobulin fc region deleted initial methionine residues
|
|
WO9937631A1
|
|
Novel taxaneterpine compounds
|
|
KR20000043714A
|
|
Stabilizer for varicella-zoster live virus vaccine
|
|
US6093814A
|
|
Process for preparation of cefdinir
|
|
WO9601262A1
|
|
Novel quinoline compound and process for preparation thereof
|
|
KR0135736B1
|
|
A stable omeprazole resin salt
|
|
EP0571400A1
|
|
Novel quinolone compounds and processes for preparation thereof
|
